- Presentations
- 0
- Brands
- 0
- Manufacturers
- 0
- Available from stock
- 0
Sugemalimab is a medicine. It is available for export supply from India to licensed hospitals, importers and physicians, with the documents the destination country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- ATC classification
- L01FF11 Sugemalimab · Cancer medicines (antineoplastics), subgroup L01F, subgroup L01FF
- US FDA first approval
- Not recorded
- EU status
- Authorised
- Orphan designation
- No
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
All presentations
No presentations of Sugemalimab are listed yet. Ask us to source it
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Questions and answers
Is Sugemalimab available for export from India?
No presentation of Sugemalimab is listed yet, but our sourcing team can check licensed channels. Send a request with the strength, quantity and destination country.
Is Sugemalimab authorised in the European Union?
Yes. Sugemalimab has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
Does Sugemalimab need cold chain shipping?
No listed presentation of Sugemalimab is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Sugemalimab in?
Sugemalimab is classified under ATC code L01FF11 (Sugemalimab).
References
- Cejemly: European public assessment report (EPAR). European Medicines Agency. Retrieved 11 November 2026
Request Sugemalimab for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.